// App-Quantinova.ai

TPS2591 : First-in-human, open label, multicenter phase I of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas.

Researchers

Presenter

  • Martine Bagot

Principal Investigators

  • Madeleine Duvic

  • Maarten Vermeer

  • Pierluigi Porcu

  • Sean Whittaker

  • Caroline Ram-Wolff

  • Christine Paiva

  • Anne Marie-Cardine

  • Cecile Bonnafous

  • Carine Paturel

  • Frederique Moriette

  • Robert Albert Zerbib

  • Armand Bensussan

  • Helene Sicard

  • Korinna Pilz

  • Youn H. Kim

Medical Centers

  • AP-HP, Hopital Saint-Louis, Unite d'Oncodermatologie, Departement de Dermatologie, Paris, France

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Leiden University Medical Centre, Leiden, Netherlands

  • Ohio State University Wexner Medical Center, Columbus, OH

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Hopital St Louis, Service de Dermatologie, Paris, France

  • Innate Pharma, Marseille, France

  • INSERM, Paris, France

  • INNATE PHARMA, Marseille, France

  • Stanford Cancer Center, Cupertino, CA

Locations

  • France

  • United States

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • T-cell lymphoma

  • Cutaneous T-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • IPH4102

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Dose Escalation

  • Cohort

  • First-In-Human

Phase

  • I

Study Id's

  • NCT02593045

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved